Request edit access
Real World Outcome of Eculizumab in Post-Kidney Transplant TMA 
Sign in to Google to save your progress. Learn more
Kindly fill out a separate Google Form/link for each patient
A. Center and respondent details
1. Name of transplant center 

2. City/state/country

City
State
Country
3. Type of Center
4. Annual Kidney Transplant Volume
5. Respondent Name/Designation
6. Contact - Email ID
7.  Contact - Mobile Number
8. Does your center maintain a transplant TMA registry?
Clear selection

B. Incidence and Prevalence

1. Total kidney transplants performed in last 5 years:

2. Number of suspected post-transplant TMA cases:

3. Number of biopsy-proven TMA cases:

4. Number of systemic TMA cases:

5. Number of kidney-limited TMA cases:

6. Timing of TMA after transplant:

7. Classification:

C. Recipient and Transplant Details

1. Recipient Age
2. Recipient Gender
Clear selection
3. Native Kidney Disease
4. History of TMA/aHUS before Transplant
Clear selection
5. Previous Graft Loss due to TMA
Clear selection
6. Donor Type
7. HLA Mismatch
8. DSA present Pre-Transplant
Clear selection
9. Induction Used
10. Maintenance Immunosuppression
11. CNI/mTOR trough level at TMA diagnosis
D. Clinical presentation
1. Presentation
2. Serum Creatinine at Diagnosis
3. Urine protein/Creatinine ratio
4. BP at Diagnosis
5. Need for Dialysis
Clear selection
E. Laboratory Diagnosis
1. Hemoglobin
2. Platelet Count
3. LDH
4. Haptoglobin
5. Reticulocyte Count
6.  Schistocytes on Peripheral Smear
Clear selection
7. Direct Coombs test
8.  C3
9. C4
10. ADAMTS13 activity tested
Clear selection
IF YES: 
RESULT
11. STEC/Shiga toxin testing done
Clear selection
IF YES: 
RESULT
12. Other Infection Identified
13. Anti-factor H Antibody Tested
Clear selection
IF YES: 
RESULT
14. Complement Genetic Testing Done
Clear selection
IF YES: 
15. Variant classification
F. Biopsy and Rejection Assessment
1. Graft Biopsy Performed
Clear selection
2. Biopsy timing from TMA Suspicion
3. Biopsy findings:
4. C4d staining
5. Microvascular Inflammation
Clear selection
6. DSA at Diagnosis
7. ABMR Diagnosed
Clear selection
8. TCMR present
Clear selection
9. Electron Microscopy Done
Clear selection
10. Final biopsy impression
G. Suspected trigger
1. Most likely trigger
2. Was more than one trigger present? 
Clear selection
H. Treatment details
1. Initial Management
2.  Was Eculizumab Used? 
Clear selection
3. Indication for Eculizumab
4. Time from Diagnosis to First Eculizumab Dose
5. Eculizumab Dosing Schedule Used
6. Number of Doses
7. Duration of Therapy
8. Was Ravulizumab Used Later? 
Clear selection
9. Reason for stopping eculizumab
10. Vaccination before Eculizumab
11. Antibiotic prophylaxis given? 
Clear selection
12. Funding source
I. Outcomes
1. Hematological Response
2. Platelet Recovery Day
3.  LDH Normalization Day
4.  Creatinine at 1 Month
5.  Creatinine at 3 Months
6.  Creatinine at 6 Months
7.  Creatinine at 12 Months
8.  Dialysis Discontinued? 
Clear selection
9.  Graft Outcome
10.  TMA Recurrence after Treatment Withdrawal
Clear selection
11.  Infection after Eculizumab
Clear selection
If Yes
Kindly name the infection
12.  Other Adverse Events
13.  Mortality
Clear selection
J. Real-world Barriers and Opinion
1.  Main Barriers to Eculizumab Use

2. In which Cases would you Consider Eculizumab?

3. Do you support Creating a National Post-Transplant TMA Registry? 
Clear selection
4.  Are you Willing to Contribute Anonymized Cases? 
Clear selection
Submit
Clear form
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. - Terms of Service - Privacy Policy

Does this form look suspicious? Report

Google Forms